Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets ...

Researchers have developed a TRBC2-targeted antibody-drug conjugate for T-cell lymphomas and leukemias, addressing half of ...

Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets ...

Peptidream Inc. has announced a new radiopharmaceutical candidate targeting cadherin-3 (CDH3) for the diagnosis and treatment of head and neck squamous cell carcinoma.

Learn more about whether Legend Biotech Corporation or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets TRBC2-positive T-cell ...

It's notable that Ipsen has bolted on more than 20 early-stage programmes since 2020 as part of a push to become a major ...

Ipsen gains exclusive global rights, outside of Greater China, for development, manufacturing and commercialization of SIM0613, a ...

A novel polycyclic aromatic hydrocarbon derivative hole selective material (4PADNC) has been designed to optimize hole ...